ForSight VISION5, a Menlo Park, CA-based developer of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy, completed a $15m Series C financing.
The round was led by H.I.G. BioVentures of Miami, Florida, with participation from existing investors Morgenthaler Ventures, Versant Ventures, Technology Partners, and Delphi Ventures. In conjunction with the funding, Aaron Davidson, of H.I.G. BioVentures joined the company’s Board of Directors.
Founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC and led by John Maroney, CEO, ForSight VISION5 has been developing the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive medication.
For it, the company has completed enrollment of over 160 subjects in a randomized, active controlled Phase 2 Study.